166 related articles for article (PubMed ID: 35223471)
1. Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.
Varadarajan I; Ballen K
Front Oncol; 2022; 12():781479. PubMed ID: 35223471
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
3. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
4. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
5. B and T cell prolymphocytic leukaemia.
Cross M; Dearden C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
[TBL] [Abstract][Full Text] [Related]
6. A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge.
Figueroa-Jiménez LA; Cabrera-Márquez AL; Báez-Díaz L; Cáceres-Perkins W
Bisturi (S Juan); 2016; 2016():12-16. PubMed ID: 29238632
[TBL] [Abstract][Full Text] [Related]
7. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.
Brothers J; Castillo DR; Jeon WJ; Joung B; Linhares Y
Hematology; 2023 Dec; 28(1):2237342. PubMed ID: 37485976
[No Abstract] [Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
Guillaume T; Beguin Y; Tabrizi R; Nguyen S; Blaise D; Deconinck E; Redjoul R; Cornillon J; Guillerm G; Contentin N; Sirvent A; Turlure P; Salmon A; Huynh A; François S; Peffault de Latour R; Yakoub-Agha I; Mohty M
Eur J Haematol; 2015 Mar; 94(3):265-9. PubMed ID: 25130897
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
[TBL] [Abstract][Full Text] [Related]
11. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
12. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
George B; Kerridge IH; Gilroy N; Huang G; Hertzberg MS; Bradstock KF; Gottlieb DJ
Transpl Infect Dis; 2012 Apr; 14(2):141-8. PubMed ID: 22283838
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
15. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
[TBL] [Abstract][Full Text] [Related]
16. How I treat prolymphocytic leukemia.
Dearden C
Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
18. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
19. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]